麦科医药(02335.HK)XTL6001研究获接纳于公认学术会议作报告

阿斯达克财经
Aug 17

麦科医药-B(02335.HK) 公布,集团其中一款主要产品XTL6001的研究成果,获接纳于糖尿病、代谢性疾病以及肾脏病领域的多场顶尖国际公认学术会议上作报告,包括第62届欧洲糖尿病研究协会年会“EASD 2026”,以及2026年美国肾脏病学会肾脏周“ASN Kidney Week 2026”。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10